Abstract
Background With COVID-19 cases peaking, COVID-19 vaccination programs starting and health systems reaching their limits in winter 2020/21, schools remained closed in many countries despite ever-recurring debates. To better understand teachers’ fear of infection and risk perception we conducted a survey in Germany.
Methods Participants were recruited through various associations and invited to take part in a cross-sectional COVID-19 specific online survey. Anonymous demographic and self-reported data were collected from those who gave their informed consent. Descriptive statistical analysis was performed. To evaluate with fear associated factors of contracting SARS-CoV-2, an adjusted multivariable regression analysis was performed.
Results 6.753 teachers gave their informed consent to answer the online survey. The median age of the teachers was 43 years with 77% being female. Most teachers worked in high schools (29%) and elementary schools (26%). Most participants (73%) feared to contract SARS-CoV-2 at school while 77% intended to be vaccinated against COVID-19. 98% considered students to pose the greatest risk. Multivariable regression analysis revealed that female and younger teachers were significantly more anxious to get infected with SARS-CoV-2 and that the odds teachers were more anxious was 9 times higher for those who favored re-opening of schools the least (p < 0.001).
Conclusions To the authors’ knowledge, this is the first study to describe teachers fear and risk perception of COVID-19 and their attitude towards vaccinations in a nationwide survey. The anxiety correlates to the COVID-19 protection measures demanded. Teachers’ fear is the driving factor and not a rational logic.
Competing Interest Statement
HM is a member of the board of directors of Weleda AG and a member of the Network Arbeitsgemeinschaft der Wissenschaftlichen Fachgesellschaften (AWMF e.V.) guideline committee for integrative oncology (Guideline for Complementary Medicine in the Treatment of Oncological Patients). HM has an endowed professorship at the Charite-Universitaetsmedizin Berlin, which is financed by the Software AG Foundation, outside the submitted work. FS reports grants from AstraZeneca, Helixor Heilmittel GmbH, Abnoba GmbH and Iscador AG, outside the submitted work; grants from AstraZeneca and Helixor Heilmittel GbmH include travel costs and honoraria for speaking. The other authors have declared that no competing interests exist. No payment was received for any other aspects of the submitted work. There are no patents, products in development, or marketed products to declare. There are no other relationships/conditions/circumstances that present potential conflicts of interest.
Funding Statement
HM is a member of the board of directors of Weleda AG and a member of the Network Arbeitsgemeinschaft der Wissenschaftlichen Fachgesellschaften (AWMF e.V.) guideline committee for integrative oncology (Guideline for Complementary Medicine in the Treatment of Oncological Patients). HM has an endowed professorship at the Charite-Universitaetsmedizin Berlin, which is financed by the Software AG Foundation, outside the submitted work. FS reports grants from AstraZeneca, Helixor Heilmittel GmbH, Abnoba GmbH and Iscador AG, outside the submitted work; grants from AstraZeneca and Helixor Heilmittel GbmH include travel costs and honoraria for speaking. The other authors have declared that no competing interests exist. No payment was received for any other aspects of the submitted work. There are no patents, products in development, or marketed products to declare. There are no other relationships/conditions/circumstances that present potential conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki.
The survey was reviewed by the Berlin Ethics Committee. Since the data in our study was collected anonymously (no code lists available, no conclusion could be drawn from the collected data to personal data) and neither patients nor test persons were included, ethical approval was waived. We refer to statutes of the Ethics Committee of the Bavarian Medical Association (Bayerische Aerztekammer).
http://ethikkommission.blaek.de/studien/sonstige-studien-15-bo/antragsunterlagen-primaerberatend
The data collection took place in accordance with the European Data Protection Regulation. Prior to participating in the survey, participants were given a description and objectives of the study. Written informed consent has been obtained from all the participants prior study enrolment. The study was approved by the institutional data protection board and quality management (Clinical Study Center (CSC) and Clinical Trial Office (CTO) of the Charite - Universitaetsmedizin Berlin) based on the given data protection concept.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The ImpfREAD surevy in German language, as well as the data that support the findings of this study are available from the corresponding author, [SW], upon reasonable request.
